安宫牛黄丸辅助治疗急性脑梗死与脑出血的Meta分析
该Meta分析检索多个数据库至2018年4月,纳入18项随机对照试验共1601例患者,评估安宫牛黄丸辅助治疗急性脑梗死和急性脑出血的疗效与安全性。结果显示,联合安宫牛黄丸可显著提高总有效率、降低神经功能缺损评分并改善格拉斯哥昏迷评分,但纳入试验方法学质量欠佳,需更多高质量试验验证。
要点
- 安宫牛黄丸辅助治疗可提高急性脑梗死和脑出血患者的总有效率。
- 联合治疗可降低神经功能缺损评分,并改善格拉斯哥昏迷评分。
- 纳入试验方法学质量欠佳,结论需谨慎解读并待高质量试验验证。
核心结论
- 安宫牛黄丸辅助治疗似可提高急性脑梗死和急性脑出血患者的总有效率并改善神经功能缺损评分。
- 因纳入试验方法学质量欠佳,仍需更多设计良好的试验验证。
研究设计与样本
- 检索Embase、PubMed、Cochrane Library、CNKI、万方和维普数据库自建库至2018年4月。
- 纳入评估安宫牛黄丸辅助治疗急性卒中的随机对照试验,共18项试验、1601例患者。
- 计算风险比(RR)或加权均数差(WMD)及其95%置信区间(CI)。
主要发现
- 与单用常规治疗相比,安宫牛黄丸联合常规治疗显著提高急性脑梗死患者的总有效率(RR 1.27;95% CI 1.14-1.41)。
- 联合治疗显著提高急性脑出血患者的总有效率(RR 1.26;95% CI 1.14-1.38)。
- 联合治疗显著降低急性脑梗死患者的神经功能缺损评分(WMD -3.64;95% CI -4.97至-2.31)。
- 联合治疗显著降低急性脑出血患者的神经功能缺损评分(WMD -3.52;95% CI -5.51至-1.54)。
- 联合治疗显著改善急性脑梗死患者的格拉斯哥昏迷评分(WMD 1.18;95% CI 0.79-1.56),并改善急性脑出血患者的格拉斯哥昏迷评分(WMD 2.28;95% CI 1.37-3.19)。
临床怎么用
- 在常规治疗基础上,可考虑联合安宫牛黄丸作为急性脑梗死和急性脑出血的辅助治疗。
- 应用时需结合患者具体情况,并关注纳入试验方法学质量欠佳带来的证据不确定性。
局限性
- 纳入试验的方法学质量欠佳。
- 需要更多设计良好的试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Angong Niuhuang Pill (ANP) is a well-known traditional Chinese patent medicine. This meta-analysis aimed to evaluate the efficacy and safety of ANP as an adjuvant therapy in patients with acute cerebral infarction (ACI) and acute intracerebral hemorrhage (AIH). MATERIALS AND METHODS: We performed a literature search in Embase, Pubmed, Cochrane Library, CNKI, Wanfang, and VIP database from their inceptions to April 2018. Randomized controlled trials evaluating ANP as an adjuvant therapy for acute stroke were selected. Risk ratio (RR) or weighted mean difference (WMD) with their 95% confidence interval (CI) was calculated between with and without ANP therapy. RESULTS: Eighteen trials involving 1,601 patients were identified and analyzed. Meta-analysis showed that ANP plus usual treatment significantly improved the total response rate in patients with ACI (RR 1.27; 95% CI 1.14-1.41) and AIH (RR 1.26; 95% CI 1.14-1.38) compared with the usual treatment alone. Adjuvant treatment with ANP also significantly reduced the neurologic deficit score in patients with ACI (WMD -3.64; 95% CI -4.97 to - 2.31) and AIH (WMD -3.52; 95% CI -5.51 to -1.54). Moreover, ANP significantly improved the Glasgow Coma Scale in patients with ACI (WMD 1.18; 95% CI 0.79-1.56) and AIH (WMD 2.28; 95% CI 1.37-3.19). CONCLUSIONS: Adjuvant treatment with ANP appears to improve the total response rate and neurologic deficit score in patients with ACI and AIH. More well-designed trials are required due to the suboptimal methodological quality of the included trials.
引用
- Liu H, Yan Y, Pang P, et al. Angong Niuhuang Pill as adjuvant therapy for treating acute cerebral infarction and intracerebral hemorrhage: A meta-analysis of randomized controlled trials. J Ethnopharmacol. 2019. PMID: 30910581. doi:10.1016/j.jep.2019.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。